Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
WESTMINSTER, Colo., Nov. 15, 2016 -- Surefire Medical, Inc. announced a grant from the Colorado Office of Economic Development and International Trade (OEDIT) to initiate a Phase 1b immunotherapy clinical trial in patients with liver cancer metastases, HITM-SURE (NCT02850536). The study, in collaboration with Roger Williams Medical Center and the University of Colorado School of Medicine, will investigate the use of the Surefire® Precision Infusion System to deliver chimeric antigen receptor T-cells (CAR-T) directly to liver metastases.
CAR-T therapy has generated impressive results in certain hematologic malignancies. However, its use is associated with severe side effects caused by systemic administration of the therapy. The HITM-SURE trial aims to determine whether precise localized delivery using the Surefire Precision Infusion System can enable the administration of a therapeutic dose for a product candidate in solid tumor while limiting known systemic side effects of CAR-T treatments.
“Administering CAR-T cells through conventional methods to achieve a therapeutic dose in solid tumor applications is not only inefficient, but also frequently limited by severe systemic side effects, such as neurotoxicity and cytokine release syndrome,” said Steven Katz, M.D., Director of the Office of Therapeutic Development at the Roger Williams Medical Center, and the principal investigator of the trial. “We hope to improve the therapeutic window for these treatments by directly administering a smaller but concentrated dose precisely at the tumor site.”
Surefire’s infusion system utilizes a semi-porous expandable tip that increases infusion pressure. In a randomized trial, the Surefire catheter was shown to improve tumor uptake by 68 percent while simultaneously decreasing non-target delivery by 58 percent. Additionally, a multi-center registry showed that the use of the Surefire Precision Infusion System to deliver therapy in the treatment of primary liver cancer (hepatocellular carcinoma or HCC) was associated with a 68 percent complete tumor response and 92 percent objective tumor response. These response rates are considerably higher when compared to the average response rates seen in the literature for this patient population.
“We are thrilled to receive this grant from the State of Colorado,” said Surefire Medical’s President and CEO James Chomas, Ph.D. “This kind of targeted support helps drive innovation and economic development in the state.”
About Surefire Medical
Surefire Medical, Inc. develops, manufactures and markets innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’s technology is designed to precisely deliver therapeutic agents through a unique microcatheter with an expandable tip that creates a pressure gradient, driving therapeutic agents deeply into the tumor while minimizing backflow that might otherwise damage healthy tissue. The Surefire Infusion System enables physicians to target tumors with superior accuracy, control and protection. The Surefire Infusion Systems and Surefire Precision have received regulatory approval in the U.S., Europe, Canada, Mexico and Brazil. For more information, please visit www.surefiremedical.com.
Edna Kaplan KOGS Communication [email protected] 781-639-1910/o
